{"id":201494,"date":"2026-08-13T15:09:46","date_gmt":"2026-08-13T09:39:46","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=201494"},"modified":"2026-08-13T15:09:48","modified_gmt":"2026-08-13T09:39:48","slug":"caplin-point-laboratories-q1-results-fy27-pat-179-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/caplin-point-laboratories-q1-results-fy27-pat-179-crore\/","title":{"rendered":"Caplin Point Laboratories Q1 FY27 Results: Revenue Rs 610 Cr, PAT Rs 179 Cr and Key Highlights"},"content":{"rendered":"
<\/div>\n

Caplin Point Laboratories Q1 FY27: Revenue Rs 610 Cr (+19.63% YoY). PAT Rs 179 Cr (+18.82% YoY). Results August 12, 2026. CMP Rs 2,468.40.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Caplin Point Laboratories reported a 19% jump in net profit to Rs 179 crore in Q1 FY27, compared with Rs 150 crore in the same quarter last year. Revenue climbed 20% to Rs 610 crore during the June 2026 quarter, with gross profit rising to Rs 191 crore. Investors should track the recovery trajectory and operating cost trends through the rest of FY27.<\/p>\n<\/div>\n

Caplin Point Laboratories Q1 FY27 results were declared on August 12, 2026, with the pharmaceuticals company reporting a net profit (PAT) of Rs 179 crore, up 18.82% from Rs 150 crore in Q1 FY26. The figures are on a consolidated basis for the quarter ended June 30, 2026.<\/p>\n

Caplin Point Laboratories’s revenue for the June 2026 quarter came in at Rs 610 crore, slightly above the Rs 510 crore reported in Q1 FY26. Gross profit for the period stood at Rs 191 crore, up from Rs 161 crore a year earlier.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n